After Receiving Young Stem Cells, Elderly Report "Feeling Much Better" — Cell Subjournal: Higher Dose, More Pronounced Effects

I recently came across a trending question: "When did you realize your parents were truly getting old?" The top-voted comment read: "When my dad said 'I can't walk that far anymore,' and when my mom had to stop three times on the stairs after coming back from grocery shopping."

But what you may not know is that this "can't walk anymore" state is medically known as frailty of aging — a bona fide pathological condition.

However, a recent clinical study published in the journal Cell Stem Cell has shown that a single infusion of stem cells significantly improved mobility in frail elderly individuals within 9 months, with remarkable results.

Many people think that feeling weak in old age is normal and that rest will fix it. But "frailty" in medicine means something entirely different. It refers to "a state of decreased physiological reserve in older adults leading to reduced stress resistance." In plain terms, even a minor event — a cold, a fall, or even a change in weather — can cause their bodies to shut down completely.

Yet frailty is a clinical syndrome that can be diagnosed and should be intervened.

Scientists have gradually identified a key thread: "inflammaging" is a major cause of frailty. Simply put, the body enters a chronic, low-grade inflammatory state. Under the continuous stimulation of this inflammation, tissues become fragile, signaling pathways become disordered, and muscles cannot receive stable blood supply and nutrition — naturally leaving people unable to walk and feeling weak.

To make matters worse, the body's stem cell population, responsible for tissue renewal and repair, is also dragged down in this process: their numbers decrease and their activity declines, making it impossible to replenish losses in a timely manner.

Therefore, to break this cycle, we must either directly regulate the inflammatory environment or supplement cells with regulatory capabilities to rebuild the body's repair capacity.

This study published in Cell Stem Cell used Laromestrocel, a mesenchymal stem cell product from the U.S. biotechnology company Longeveron.

Researchers recruited 148 mildly to moderately frail adults aged 70 to 85, divided them into five groups, and infused each with either a placebo or different doses of stem cells (ranging from 25 million to 200 million cells). After one year of observation, they found a clear "dose-response" relationship: the higher the dose, the more pronounced the effect.

A single infusion of Laromestrocel improved the 6-minute walk distance of frail elderly individuals in a dose-dependent and time-dependent manner, with the most significant effect at 9 months and the 200 million cell dose being optimal.

Among the four dose groups (25 million, 50 million, 100 million, and 200 million cells), the highest dose group (200 million cells) walked 41.3 meters more than the placebo group — already approaching the clinically meaningful improvement threshold. By 9 months, the gap widened dramatically: the 200 million cell dose group walked 63.4 meters more than the placebo group, with a highly statistically significant difference (p=0.0077). The 50 million cell dose group also performed well, walking 49.2 meters more at 9 months (p=0.0122).

Interestingly, the elderly participants' subjective feelings were also significant. They generally reported "feeling much better," which correlated strongly with the increase in walking distance.

The efficacy data alone makes this a solid clinical trial. But what truly elevates the value of this study is that the researchers also identified an "efficacy predictor" — soluble TIE2 (sTIE2).

TIE2 is a receptor on vascular endothelial cells responsible for receiving anti-inflammatory signals. Under normal conditions, TIE2 functions on the cell surface. However, when blood vessels are damaged and inflammation erupts, enzymes called matrix metalloproteinases (MMPs) are activated. Like scissors, they cut TIE2 off the cell surface into fragments that fall into the bloodstream — this is sTIE2.

Therefore, the level of sTIE2 in the blood directly reflects the degree of vascular damage. Higher levels mean more TIE2 has been cut off, worse vascular endothelial status, and more severe inflammatory response.

The researchers found that elderly individuals who received stem cell therapy had significantly reduced sTIE2 levels in their blood. Particularly in the 100 million cell dose group, levels dropped by more than 560 pg/mL at 9 months. Again, the higher the dose, the more pronounced the effect.

Laromestrocel reduces serum sTIE2 levels in a dose-dependent manner, providing biomarker evidence for improved vascular function and anti-inflammaging.

The researchers believe that stem cells themselves secrete large amounts of a protein called tissue inhibitor of metalloproteinases 2 (TIMP2), which 恰好 inhibits the activity of MMPs. When MMPs are inhibited, the amount of TIE2 being cleaved naturally decreases, allowing the vascular endothelium to remain intact and inflammatory signals to be controlled. This explains why sTIE2 levels dropped in the treated elderly participants.

Of course, no therapy is without limitations. This study also showed that while Laromestrocel performed excellently on endurance metrics (6-minute walk), it did not significantly improve explosive power (4-meter gait speed) or strength (grip strength). The researchers speculate this may be related to the mechanism of action of stem cells: they repair blood vessels and improve tissue oxygen supply, and endurance type I muscle fibers are highly dependent on blood perfusion and oxygen supply. In contrast, strength type II muscle fibers are less dependent on blood supply and thus benefit less.

Nevertheless, for the daily lives of the elderly, improved endurance is far more important than grip strength.

With proven efficacy and a clear mechanism, the final question is: when will ordinary people be able to access this treatment?

This brings us to Longeveron, the company developing the cell product.

Longeveron was also selected as a semi-finalist in the XPRIZE Healthspan Project and won the first-phase Top 40 Milestone Award. The judging committee selected it as one of the top 40 semi-finalists based on the feasibility of its stem cell therapy.

Laromestrocel is their core product Lomecel-B™, developed as an "off-the-shelf" therapy. The stem cells are derived from the bone marrow of healthy adults aged 18-45, expanded, quality-tested, and frozen into ready-to-use medications. When needed, they are simply thawed and infused — patients do not need to have their own bone marrow drawn or wait for cell culture.

This is a critical leap from "personalized customization" to "standardized mass production" for cell therapies. Only with large-scale production can costs be reduced.

Of course, bone marrow is not the only source of stem cells. Perinatal umbilical cord and placenta tissues allow for non-invasive extraction and yield younger, more proliferative cells, but standardization and quality control present additional challenges. Adult adipose-derived stem cells are easy to obtain, but there is significant variability between donors and extraction sites. Induced pluripotent stem cell (iPS) technology, in theory, allows for unlimited expansion and standardized production, but has higher technical and safety barriers and faces more cautious regulatory oversight.

Longeveron's ambitions extend beyond aging frailty. They are advancing the same product for the treatment of Alzheimer's disease and pediatric rare heart diseases, following a consistent logic: using the anti-inflammatory and repair capabilities of mesenchymal stem cells to address diseases deeply linked to aging and inflammation. Before this study was published, Longeveron had already listed on the NASDAQ (ticker symbol LGVN), and its Alzheimer's disease program received FDA Regenerative Medicine Advanced Therapy (RMAT) designation.

That said, there is still a long way to go before this therapy is covered by insurance or available in community clinics. After phase 2b comes the costly phase 3 trial, followed by real-world data tracking after approval. Furthermore, the term "stem cells" has been tarnished for years by unregulated underground clinics, leaving many people either afraid to use them or unable to afford them. Spending large sums to treat frailty — a condition that many do not even consider a "disease" — will also take time for public acceptance.

But the direction is clear. Turning stem cells into ready-to-use medications and tackling one age-related disease after another is itself a major breakthrough.

The trillion-dollar longevity industry blue ocean has fully opened. How to identify the right track and achieve stable profitability amid this trend? The Longevity Clinic Transformation Executive Program is now officially launched. The course focuses on core transformation needs, optimizing product, service, and brand potential, and dissecting three replicable operational levers: marketing, compensation, and sales. Taught face-to-face by industry frontline operators, it covers compliant transformation and practical business insights, with special sessions including on-site visits to longevity clinics and in-depth analysis of billion-dollar revenue classic cases. From top-level strategic planning to on-the-ground implementation, it empowers cell institutions to transform smoothly and operate profitably across the entire value chain.

This executive program is precisely tailored for entrepreneurs looking to enter the longevity industry compliantly, cell clinic operators seeking transformation breakthroughs, and investors 布局 the big health cell track. It helps you deeply connect with high-quality compliant industry resources, build a high-end practical exchange platform, and break industry information barriers to achieve precise resource interoperability.

[1] Ruiz, J.G., et al., Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty. Cell Stem Cell, 2026. 33(3): p. 393–404.e4.